<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33329145</PMID><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-0640</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Frontiers in psychiatry</Title><ISOAbbreviation>Front Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Can Kratom (<i>Mitragyna speciosa</i>) Alleviate COVID-19 Pain? A Case Study.</ArticleTitle><Pagination><StartPage>594816</StartPage><MedlinePgn>594816</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">594816</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpsyt.2020.594816</ELocationID><Abstract><AbstractText>Among the symptoms of COVID-19 fever, general malaise, pain and aches, myalgia, fatigue, and headache can affect the quality of life of patients, even after the end of the acute phase of the infection and can be long lasting. The current treatment of these symptoms, also because COVID-19 patients have been asked not to use non-steroidal anti-inflammatory drugs (NSAIDs), in particular ibuprofen are often unsatisfactory. Among the above mentioned symptoms malaise and fatigue seem the most difficult to treat. In this case report we describe the use of kratom (<i>Mitragyna speciosa</i>) by a patient with confirmed COVID-19 infection. What we observed was a fast and sustained relieve of the above mentioned symptoms.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Metastasio, Prevete, Singh, Grundmann, Prozialeck, Veltri, Bersani and Corazza.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Metastasio</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHS Camden and Islington Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prevete</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Darshan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Drug Research, Universiti Sains Malaysia, Minden, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grundmann</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prozialeck</LastName><ForeName>Walter C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Midwestern University, Downers Grove, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veltri</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, Midwestern University, Glendale, AZ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bersani</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corazza</LastName><ForeName>Ornella</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Psychiatry</MedlineTA><NlmUniqueID>101545006</NlmUniqueID><ISSNLinking>1664-0640</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">kratom</Keyword><Keyword MajorTopicYN="N">long covid</Keyword><Keyword MajorTopicYN="N">new psychoactive substances</Keyword><Keyword MajorTopicYN="N">new treatments</Keyword><Keyword MajorTopicYN="N">opioid</Keyword><Keyword MajorTopicYN="N">stimulants</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>17</Day><Hour>5</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33329145</ArticleId><ArticleId IdType="pmc">PMC7717955</ArticleId><ArticleId IdType="doi">10.3389/fpsyt.2020.594816</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang X, Wei F, Hu L, Wen L, Chen K. Epidemiology and clinical characteristics of COVID-19. Arch. Iran Med. (2020) 23:268&#x2013;71. 10.34172/aim.2020.09</Citation><ArticleIdList><ArticleId IdType="doi">10.34172/aim.2020.09</ArticleId><ArticleId IdType="pubmed">32271601</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J. Gen. Intern. Med. (2020) 35:1545&#x2013;49. 10.1007/s11606-020-05762-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-020-05762-w</ArticleId><ArticleId IdType="pmc">PMC7088708</ArticleId><ArticleId IdType="pubmed">32133578</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore N, Carleton B, Blin P, Bosco-Levy P, Droz C. Does Ibuprofen worsen COVID-19? Drug Saf. (2020) 43:611&#x2013;4. 10.1007/s40264-020-00953-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-020-00953-0</ArticleId><ArticleId IdType="pmc">PMC7287029</ArticleId><ArticleId IdType="pubmed">32529474</ArticleId></ArticleIdList></Reference><Reference><Citation>Pergolizzi JV, Jr, Varrassi G, Magnusson P, Lequang JA, Paladini A, Taylor R, et al. . COVID-19 and NSAIDS: a narrative review of knowns and unknowns. Pain Ther. (2020) 1&#x2013;6. 10.1007/s40122-020-00173-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40122-020-00173-5</ArticleId><ArticleId IdType="pmc">PMC7245573</ArticleId><ArticleId IdType="pubmed">32447629</ArticleId></ArticleIdList></Reference><Reference><Citation>Micallef J, Soeiro T, Jonville-B&#xe9;ra AP. Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection. Therapie. (2020) 75:355&#x2013;62. 10.1016/j.therap.2020.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.therap.2020.05.003</ArticleId><ArticleId IdType="pmc">PMC7204680</ArticleId><ArticleId IdType="pubmed">32418728</ArticleId></ArticleIdList></Reference><Reference><Citation>Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J. Microbiol. Immunol. Infect. (2020) 53:436&#x2013;43. 10.1016/j.jmii.2020.03.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2020.03.034</ArticleId><ArticleId IdType="pmc">PMC7129535</ArticleId><ArticleId IdType="pubmed">32307245</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenkens M, de Wit H, Danser AH, Esselink AC, Horikx A, Ten Oever J, et al. . Geneesmiddelen bij COVID-19 [medication and comedication in COVID-19 patients]. Ned. Tijdschr. Geneeskd. (2020) 164:D4995.</Citation><ArticleIdList><ArticleId IdType="pubmed">32324352</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakodkar P, Kaka N, Baig MN. A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19). Cureus. (2020) 12:e7560. 10.7759/cureus.7560</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.7560</ArticleId><ArticleId IdType="pmc">PMC7138423</ArticleId><ArticleId IdType="pubmed">32269893</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav. Immun. (2020) 87:59&#x2013;73. 10.1016/j.bbi.2020.04.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.04.046</ArticleId><ArticleId IdType="pmc">PMC7175848</ArticleId><ArticleId IdType="pubmed">32334062</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertisch S, Ellerin T, Farid H.
Coronavirus Resource Center-Harvard Health Publishing (2020). Available online at: https://www.health.harvard.edu/diseases-and-conditions/coronavirus-resource-center (accessed October 21, 2020).</Citation></Reference><Reference><Citation>Kutti Sridharan G, Kotagiri R, Chandiramani VH, Mohan BP, Vegunta R, Vegunta R, et al. . COVID-19 and avoiding Ibuprofen. How good is the evidence? Am. J. Ther. (2020) 27:e400&#x2013;2. 10.1097/MJT.0000000000001196</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MJT.0000000000001196</ArticleId><ArticleId IdType="pmc">PMC7242088</ArticleId><ArticleId IdType="pubmed">32366740</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallen T.
COVID-19 Ibuprofen Fears Hit Advil Sales In GSK's Q2 (2020). Available online at: https://hbw.pharmaintelligence.informa.com/RS150301/COVID-19-Ibuprofen-Fears-Hit-Advil-Sales-In-GSKs-Q2 (accessed October 21, 2020).</Citation></Reference><Reference><Citation>Bath R, Bucholz T, Buros AF, Singh D, Smith KE, Veltri CA, et al. . Self-reported health diagnoses and demographic correlates with kratom use: results from an online survey. J. Addict. Med. (2020) 14:244&#x2013;52. 10.1097/ADM.0000000000000570</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ADM.0000000000000570</ArticleId><ArticleId IdType="pmc">PMC7446542</ArticleId><ArticleId IdType="pubmed">31567595</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh D, Narayanan S, Muller CP, Swogger MT, Chear NJY, Dzulkapli EB, et al. . Motives for using kratom (Mitragyna speciosa Korth.) among regular users in Malaysia. J. Ethnopharmacol. (2019) 233:34&#x2013;40. 10.1016/j.jep.2018.12.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2018.12.038</ArticleId><ArticleId IdType="pubmed">30594604</ArticleId></ArticleIdList></Reference><Reference><Citation>Shellard EJ. The alkaloids of Mitragyna with special reference to those of Mitragyna speciosa, Korth. Bull. Narc. (1974) 26:41&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">4607551</ArticleId></ArticleIdList></Reference><Reference><Citation>Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem. Pharm. Bull. (2004) 52:916&#x2013;28. 10.1248/cpb.52.916</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/cpb.52.916</ArticleId><ArticleId IdType="pubmed">15304982</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruegel AC, Grundmann O. The medicinal chemistry and neuropharmacology of kratom: a preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. (2018) 134(Pt A):108&#x2013;20. 10.1016/j.neuropharm.2017.08.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2017.08.026</ArticleId><ArticleId IdType="pubmed">28830758</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto K, Horie S. Analgesic effects of mitragynine and analogs. In: Raffa RB. editor. Kratom and Other Mitragynines (2014). p. 177&#x2013;94.</Citation></Reference><Reference><Citation>Matsumoto K, Horie S, Ishikawa H, Takayama H, Aimi N, Ponglux D, et al. . Antinociceptive effect of 7-hydroxymitragynine in mice: discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sci. (2004) 74:2143&#x2013;55. 10.1016/j.lfs.2003.09.054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2003.09.054</ArticleId><ArticleId IdType="pubmed">14969718</ArticleId></ArticleIdList></Reference><Reference><Citation>Saingam D, Assanangkornchai S, Geater AF, Balthip Q. Pattern and consequences of krathom (Mitragyna speciosa Korth.) use among male villagers in southern Thailand: a qualitative study. Int. J. Drug Policy. (2013) 24:351&#x2013;8. 10.1016/j.drugpo.2012.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugpo.2012.09.004</ArticleId><ArticleId IdType="pubmed">23083922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad K, Aziz Z. Mitragyna speciosa use in the northern states of Malaysia: a cross-sectional study. J. Ethnopharmacol. (2012) 141:446&#x2013;50. 10.1016/j.jep.2012.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2012.03.009</ArticleId><ArticleId IdType="pubmed">22440259</ArticleId></ArticleIdList></Reference><Reference><Citation>Leong Bin Abdullah MFI, Tan KL, Mohd IS, Yusoff NS, Chear NJY, Singh D. Lipid profile of regular kratom (Mitragyna speciosa Korth.) users in the community setting. PLoS ONE. (2020) 15:e0234639. 10.1371/journal.pone.0234639</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0234639</ArticleId><ArticleId IdType="pmc">PMC7289408</ArticleId><ArticleId IdType="pubmed">32525924</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundmann O. Patterns of kratom use and health impact in the US-results from an online survey. Drug Alcohol. Depend. (2017) 176:63&#x2013;70. 10.1016/j.drugalcdep.2017.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2017.03.007</ArticleId><ArticleId IdType="pubmed">28521200</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. Kratom (Mitragyna speciosa): user demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend. (2020) 208:107849. 10.1016/j.drugalcdep.2020.107849</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2020.107849</ArticleId><ArticleId IdType="pmc">PMC7423016</ArticleId><ArticleId IdType="pubmed">32029298</ArticleId></ArticleIdList></Reference><Reference><Citation>Coe MA, Pillitteri JL, Sembower MA, Gerlach KK, Henningfield JE. Kratom as a substitute for opioids: results from an online survey. Drug Alcohol Depend. (2019) 202:24&#x2013;32. 10.1016/j.drugalcdep.2019.05.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2019.05.005</ArticleId><ArticleId IdType="pubmed">31284119</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicknasingam B, Chooi WT, Rahim AA, Ramachandram D, Singh D, et al. . Kratom and pain tolerance: a randomized, placebo-controlled, double-blind study. Yale J. Biol. Med. (2020) 93:229&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309661</ArticleId><ArticleId IdType="pubmed">32607084</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh D, M&#xfc;ller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. (2014) 139:132&#x2013;7. 10.1016/j.drugalcdep.2014.03.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2014.03.017</ArticleId><ArticleId IdType="pubmed">24698080</ArticleId></ArticleIdList></Reference><Reference><Citation>Anwar M, Law R, Schier J. Notes from the field: kratom (Mitragyna speciosa) exposures reported to poison centers - United States, 2010-2015. MMWR Morb. Mortal. Wkly. Rep. (2016) 65:748&#x2013;9. 10.15585/mmwr.mm6529a4</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6529a4</ArticleId><ArticleId IdType="pubmed">27466822</ArticleId></ArticleIdList></Reference><Reference><Citation>Corkery JM, Streete P, Claridge H, Goodair C, Papanti D, Orsolini L, et al. . Characteristics of deaths associated with kratom use. J. Psychopharmacol. (2019) 33:1102&#x2013;23. 10.1177/0269881119862530</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881119862530</ArticleId><ArticleId IdType="pubmed">31429622</ArticleId></ArticleIdList></Reference><Reference><Citation>Henningfield JE, Grundmann O, Babin JK, Fant RV, Wang DW, Cone EJ. Risk of death associated with kratom use compared to opioids. Prev. Med. (2019) 128:105851. 10.1016/j.ypmed.2019.105851</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2019.105851</ArticleId><ArticleId IdType="pubmed">31647958</ArticleId></ArticleIdList></Reference><Reference><Citation>Raja Aziddin RE, Mustafa MR, Mohamed Z, Mohd MA.
Anti-Inflammatory Properties of Mitragyna Speciosa Extract. MJS (2005) 24:191&#x2013;4. Available online at: https://mjs.um.edu.my/article/view/8971 (accessed October 08, 2020).</Citation></Reference><Reference><Citation>Shaik Mossadeq WM, Sulaiman MR, Tengku Mohamad TA, Chiong HS, Zakaria ZA, Jabit ML, et al. . Anti-inflammatory and antinociceptive effects of Mitragyna speciosa Korth methanolic extract. Med. Princ. Pract. (2009) 18:378&#x2013;84. 10.1159/000226292</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000226292</ArticleId><ArticleId IdType="pubmed">19648761</ArticleId></ArticleIdList></Reference><Reference><Citation>Utar Z, Majid MI, Adenan MI, Jamil MF, Lan TM. Mitragynine inhibits the COX-2 mRNA expression and prostaglandin E2 production induced by lipopolysaccharide in RAW264.7 macrophage cells. J. Ethnopharmacol. (2011) 136:75&#x2013;82. 10.1016/j.jep.2011.04.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2011.04.011</ArticleId><ArticleId IdType="pubmed">21513785</ArticleId></ArticleIdList></Reference><Reference><Citation>Chittrakarn S, Keawpradub N, Sawangjaroen K, Kansenalak S, Janchawee B. (2010). The neuromuscular blockade produced by pure alkaloid, mitragynine and methanol extract of kratom leaves (Mitragyna speciosa Korth.). J. Ethnopharmacol. 129:344&#x2013;9. 10.1016/j.jep.2010.03.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2010.03.035</ArticleId><ArticleId IdType="pubmed">20371282</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsarraf E, Myers J, Culbreth S, Fanikos J. Kratom from head to toe&#x2014;case reviews of adverse events and toxicities. Curr. Emer. Hosp. Med. Rep. (2019) 7:141&#x2013;68. 10.1007/s40138-019-00194-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40138-019-00194-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldyab M, Ells PF, Bui R, Chapman TD, Lee H. Kratom-induced cholestatic liver injury mimicking anti-mitochondrial antibody-negative primary biliary cholangitis: a case report and review of literature. Gastroenterol. Res. (2019) 12:211&#x2013;5. 10.14740/gr1204</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/gr1204</ArticleId><ArticleId IdType="pmc">PMC6731044</ArticleId><ArticleId IdType="pubmed">31523332</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes CT, Iqbal U, Tighe SP, Ahmed A. Kratom-induced cholestatic liver injury and its conservative management. J. Investig. Med. High Impact Case Rep. (2019) 7:2324709619836138. 10.1177/2324709619836138</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2324709619836138</ArticleId><ArticleId IdType="pmc">PMC6440031</ArticleId><ArticleId IdType="pubmed">30920318</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborne CS, Overstreet AN, Rockey DC, Schreiner AD. Drug-induced liver injury caused by Kratom use as an alternative pain treatment amid an ongoing opioid epidemic. J. Investig. Med. High Impact Case Rep. (2019) 7:2324709619826167. 10.1177/2324709619826167</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2324709619826167</ArticleId><ArticleId IdType="pmc">PMC6350132</ArticleId><ArticleId IdType="pubmed">30791718</ArticleId></ArticleIdList></Reference><Reference><Citation>Schimmel J, Dart RC. Kratom (Mitragyna Speciosa) liver injury: a comprehensive review. Drugs. (2020) 80:263&#x2013;83. 10.1007/s40265-019-01242-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-019-01242-6</ArticleId><ArticleId IdType="pubmed">31919755</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following kratom (Mitragynina speciosa Korth) exposure. Toxicol. Obs. (2010) 6:424&#x2013;6. 10.1007/s13181-010-0079-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13181-010-0079-5</ArticleId><ArticleId IdType="pmc">PMC3550469</ArticleId><ArticleId IdType="pubmed">20411370</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzal H, Esang M, Rahman S. A case of kratom-induced Seizures. Cureus. (2020) 12:e6588. 10.7759/cureus.6588</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.6588</ArticleId><ArticleId IdType="pmc">PMC7001130</ArticleId><ArticleId IdType="pubmed">32051800</ArticleId></ArticleIdList></Reference><Reference><Citation>Labryer L, Sharma R, Chaudhari KS, Talsania M, Scofield RH. Kratom, an emerging drug of abuse, raises prolactin and causes secondary hypogonadism: case report. J. Investig. Med. High Impact Case Rep. (2018) 6:2324709618765022. 10.1177/2324709618765022</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2324709618765022</ArticleId><ArticleId IdType="pmc">PMC5858613</ArticleId><ArticleId IdType="pubmed">29568783</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheleg SV, Collins GB. A coincidence of addiction to &#x201c;kratom&#x201d; and severe primary hypothyroidism. J. Addict. Med. (2011) 5:300&#x2013;1. 10.1097/ADM.0b013e318221fbfa</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ADM.0b013e318221fbfa</ArticleId><ArticleId IdType="pubmed">21817918</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo A, Payne JD, Nugent K. Posterior reversible leukoencephalopathy syndrome after kratom ingestion. Bayl. Univ. Med. Cent. Proc. (2017) 30:355&#x2013;7. 10.1080/08998280.2017.11929647</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08998280.2017.11929647</ArticleId><ArticleId IdType="pmc">PMC5468044</ArticleId><ArticleId IdType="pubmed">28670086</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo O, Roider G, St&#xf6;ver A, Graw M, Musshoff F, Sachs H, et al. . Mitragynine concentrations in two fatalities. Forensic Sci. Int. (2017) 271:e1&#x2013;7. 10.1016/j.forsciint.2016.12.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.forsciint.2016.12.020</ArticleId><ArticleId IdType="pubmed">28089300</ArticleId></ArticleIdList></Reference><Reference><Citation>Overbeek DL, Abraham J, Munzer BW. Kratom (Mitragynine) ingestion requiring naloxone reversal. Clin. Pract. Cases Emerg. Med. (2019) 3:24&#x2013;6. 10.5811/cpcem.2018.11.40588</Citation><ArticleIdList><ArticleId IdType="doi">10.5811/cpcem.2018.11.40588</ArticleId><ArticleId IdType="pmc">PMC6366391</ArticleId><ArticleId IdType="pubmed">30775658</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong A, Mun M. A case of kratom overdose in a pediatric patient. Case Rep. Psychiatr. (2020) 2020:8818095. 10.1155/2020/8818095</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/8818095</ArticleId><ArticleId IdType="pmc">PMC7443027</ArticleId><ArticleId IdType="pubmed">32855833</ArticleId></ArticleIdList></Reference><Reference><Citation>Neerman MF, Frost RE, Deking J. A drug fatality involving kratom. J. Forensic Sci. (2013) 58(Suppl 1):S278&#x2013;9. 10.1111/1556-4029.12009</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1556-4029.12009</ArticleId><ArticleId IdType="pubmed">23082895</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal G, Robertson E, Mckinlay J, Walter E. Death from kratom toxicity and the possible role of intralipid. J. Intensive Care Soc. (2018) 19:61&#x2013;3. 10.1177/1751143717712652</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1751143717712652</ArticleId><ArticleId IdType="pmc">PMC5810870</ArticleId><ArticleId IdType="pubmed">29456604</ArticleId></ArticleIdList></Reference><Reference><Citation>Gershman K, Timm K, Frank M, Lampi L, Melamed J, Gerona R, et al. . Deaths in Colorado attributed to kratom. N. Engl. J. Med. (2019) 380:97&#x2013;8. 10.1056/NEJMc1811055</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1811055</ArticleId><ArticleId IdType="pmc">PMC6688840</ArticleId><ArticleId IdType="pubmed">30601742</ArticleId></ArticleIdList></Reference><Reference><Citation>Matson M, Schenk N. Fatality of 33-year-old man involving kratom toxicity. J. Forensic Sci. (2019) 64:1933&#x2013;5. 10.1111/1556-4029.14082</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1556-4029.14082</ArticleId><ArticleId IdType="pubmed">31121058</ArticleId></ArticleIdList></Reference><Reference><Citation>Arndt T, Claussen U, G&#xfc;ssregen B, Schr&#xf6;fel S, St&#xfc;rzer B, Werle A, et al. . Kratom alkaloids and O-desmethyltramadol in urine of a &#x201c;Krypton&#x201d; herbal mixture consumer. Forensic Sci Int. (2011) 208:47&#x2013;52. 10.1016/j.forsciint.2010.10.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.forsciint.2010.10.025</ArticleId><ArticleId IdType="pubmed">21112167</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbis-Reig D. A case report of kratom addiction and withdrawal. WMJ. (2016) 115:49&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">27057581</ArticleId></ArticleIdList></Reference><Reference><Citation>Khazaeli A, Jerry JM, Vazirian M. Treatment of kratom withdrawal and addiction with buprenorphine. J. Addict Med. (2018) 12:493&#x2013;5. 10.1097/ADM.0000000000000435</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ADM.0000000000000435</ArticleId><ArticleId IdType="pubmed">30383616</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe A, Kerr PL. A complex case of kratom dependence, depression, and chronic pain in opioid use disorder: effects of buprenorphine in clinical management. J Psychoactive Drugs. (2020) 17:1&#x2013;6. 10.1080/02791072.2020.1773586</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02791072.2020.1773586</ArticleId><ArticleId IdType="pubmed">32546067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay L, Abrahams R. Novel case of maternal and neonatal kratom dependence and withdrawal. Can. Fam. Physician. (2018) 64:121&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964386</ArticleId><ArticleId IdType="pubmed">29449242</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson L, Rawat M, Stojanovski S, Chandrasekharan P. Natural drugs, not so natural effects: Neonatal abstinence syndrome secondary to &#x2018;kratom&#x2019;. J. Neonatal. Perinatal. Med. (2019) 12:109&#x2013;12. 10.3233/NPM-1863</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/NPM-1863</ArticleId><ArticleId IdType="pmc">PMC6484255</ArticleId><ArticleId IdType="pubmed">30149482</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh D, Narayanan S, M&#xfc;ller CP, Swogger MT, Rahim AA, Leong Bin Abdullah MFI, et al. . Severity of kratom (Mitragyna speciosa Korth.) psychological withdrawal symptoms. J. Psychoactive Drugs. (2018) 50:445&#x2013;450. 10.1080/02791072.2018.1511879</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02791072.2018.1511879</ArticleId><ArticleId IdType="pubmed">30152738</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh D, Narayanan S, Vicknasingam BK, Prozialeck WC, Ramanathan S, Zainal H, et al. . Severity of pain and sleep problems during kratom (Mitragyna speciosa Korth.) cessation among regular kratom users. J. Psychoactive Drugs. (2018) 50:266&#x2013;74. 10.1080/02791072.2018.1443234</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02791072.2018.1443234</ArticleId><ArticleId IdType="pubmed">29558272</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller E, Hillemacher T, M&#xfc;ller CP. Kratom instrumentalization for severe pain self-treatment resulting in addiction - a case report of acute and chronic subjective effects. Heliyon. (2020) 6:e04507 10.1016/j.heliyon.2020.e04507</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2020.e04507</ArticleId><ArticleId IdType="pmc">PMC7378692</ArticleId><ArticleId IdType="pubmed">32715144</ArticleId></ArticleIdList></Reference><Reference><Citation>Saref A, Suraya S, Singh D, Grundmann O, Narayanan S, Swogger MT, et al. . Self-reported prevalence and severity of opioid and kratom (Mitragyna speciosa korth.) side effects. J. Ethnopharmacol. (2019) 238:111876. 10.1016/j.jep.2019.111876</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2019.111876</ArticleId><ArticleId IdType="pubmed">31014959</ArticleId></ArticleIdList></Reference><Reference><Citation>Prozialeck WC, Edwards JR, Lamar PC, Plotkin BJ, Sigar IM, Grundmann O, et al. . Evaluation of the mitragynine content, levels of toxic metals and the presence of microbes in kratom products purchased in the western suburbs of Chicago. Int. J. Environ. Res. Publ. Health. (2020) 17:5512. 10.3390/ijerph17155512</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17155512</ArticleId><ArticleId IdType="pmc">PMC7432033</ArticleId><ArticleId IdType="pubmed">32751712</ArticleId></ArticleIdList></Reference><Reference><Citation>Eastlack SC, Cornett EM, Kaye AD. Kratom-pharmacology, clinical implications, and outlook: a comprehensive review. Pain Ther. (2020) 9:55&#x2013;69. 10.1007/s40122-020-00151-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40122-020-00151-x</ArticleId><ArticleId IdType="pmc">PMC7203303</ArticleId><ArticleId IdType="pubmed">31994019</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto K, Hatori Y, Murayama T, Tashima K, Wongseripipatana S, Misawa K, et al. . Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa. Eur. J. Pharmacol. (2006) 549:63&#x2013;70. 10.1016/j.ejphar.2006.08.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2006.08.013</ArticleId><ArticleId IdType="pubmed">16978601</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto K, Mizowaki M, Suchitra T, Murakami Y, Takayama H, Sakai S, et al. . Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems. Eur. J. Pharmacol. (1996) 317:75&#x2013;81. 10.1016/S0014-2999(96)00714-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-2999(96)00714-5</ArticleId><ArticleId IdType="pubmed">8982722</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction. (2008) 103:1048&#x2013;50. 10.1111/j.1360-0443.2008.02209.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1360-0443.2008.02209.x</ArticleId><ArticleId IdType="pmc">PMC3670991</ArticleId><ArticleId IdType="pubmed">18482427</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin KY, Mark-Lee WF. A review on the antinociceptive effects of Mitragyna speciosa and its derivatives on animal model. Curr. Drug Targets. (2018) 19:1359&#x2013;65. 10.2174/1389450118666170925154025</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450118666170925154025</ArticleId><ArticleId IdType="pubmed">28950813</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson LL, Harris HM, Eans SO, Brice-Tutt A, et al. . Lyophilized kratom tea as a therapeutic option for opioid dependence. Drug Alcohol Depend. (2020) 216:108310. 10.1016/j.drugalcdep.2020.108310</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2020.108310</ArticleId><ArticleId IdType="pubmed">33017752</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh D, M&#xfc;ller CP, Murugaiyah V, Hamid SBS, Vicknasingam BK, Avery B, et al. . Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia. J. Ethnopharmacol. (2018) 214:197&#x2013;206. 10.1016/j.jep.2017.12.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2017.12.017</ArticleId><ArticleId IdType="pubmed">29248450</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>